ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer

Journal article

Open access

Peer reviewed

K. Fujiwara, H.-H. Chou, J.-W. Kim, D.S. Tan, K. Tamura, N. Katsumata, K. Harano, K. Hasegawa, S. Hume, E. Jones, …

Annals of oncology, Vol.30, pp.ix88-ix89

11/2019

Files and links (1)

url

https://doi.org/10.1093/annonc/mdz426.038View

Published (Version of record) Open

1 Record Views

Title: ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Creators: K. Fujiwara - Saitama Medical University
H.-H. Chou - Chang Gung Memorial Hospital
J.-W. Kim
D.S. Tan
K. Tamura - Breast and Medical Oncology, National Cancer Center Hospital (NCCH), Tokyo, Japan
N. Katsumata - Nippon Medical School Musashi Kosugi Hospital
K. Harano - National Cancer Center Hospital East
K. Hasegawa - Saitama Medical University
S. Hume - Clovis Oncology
E. Jones - Clovis Oncology
S. Goble - Clovis Oncology
L. Sullivan - Clovis Oncology
D. Shih - Clovis Oncology
R.L. Coleman
I. McNeish - Imperial College London
B. Monk - The US Oncology Network
R. Kristeleit - Oncology, University College London Cancer Institute, UCL, London, UK
Publication Details: Annals of oncology, Vol.30, pp.ix88-ix89
Identifiers: 991005969155002656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article